scholarly journals Sonochemical synthesis of polyoxometalate-stabilized gold nanoparticles for point-of-care determination of acetaminophen levels: preclinical study in an animal model

RSC Advances ◽  
2020 ◽  
Vol 10 (28) ◽  
pp. 16805-16816
Author(s):  
Tahereh Rohani Bastami ◽  
Abolphazl Ghaedi ◽  
Scott G. Mitchell ◽  
Aida Javadian-Saraf ◽  
Mohammad Karimi
Keyword(s):  
Gold Nanoparticles ◽  
Animal Model ◽  
Clinical Diagnosis ◽  
Point Of Care ◽  
Preclinical Study ◽  
Sonochemical Synthesis ◽  
Serum Samples ◽  
Over The Counter ◽  
Pharmaceutical Tablets

The aim of this study is the accurate detection of acetaminophen (AP) for point-of-care (POC) clinical diagnosis. The concentration of acetaminophen was measured in over-the-counter pharmaceutical tablets and in serum samples taken from mice.

scholarly journals Correction: Sonochemical synthesis of polyoxometalate-stabilized gold nanoparticles for point-of-care determination of acetaminophen levels: preclinical study in an animal model

RSC Advances ◽  
2020 ◽  
Vol 10 (31) ◽  
pp. 18138-18138
Author(s):  
Tahereh Rohani Bastami ◽  
Abolphazl Ghaedi ◽  
Scott G. Mitchell ◽  
Aida Javadian-Saraf ◽  
Mohammad Karimi
Keyword(s):  
Gold Nanoparticles ◽  
Animal Model ◽  
Point Of Care ◽  
Preclinical Study ◽  
Sonochemical Synthesis

Correction for ‘Sonochemical synthesis of polyoxometalate-stabilized gold nanoparticles for point-of-care determination of acetaminophen levels: preclinical study in an animal model’ by Tahereh Rohani Bastami et al., RSC Adv., 2020, 10, 16805–16816, DOI: 10.1039/D0RA00931H.

Determination of ascorbic acid in serum samples by screen-printed carbon electrodes modified with gold nanoparticles

Talanta ◽  
2017 ◽  
Vol 174 ◽  
pp. 733-737 ◽  
Author(s):  
M. Asunción Alonso-Lomillo ◽  
Olga Domínguez-Renedo ◽  
Abraham Saldaña-Botín ◽  
M. Julia Arcos-Martínez
Keyword(s):  
Gold Nanoparticles ◽  
Ascorbic Acid ◽  
Carbon Electrodes ◽  
Serum Samples ◽  
Screen Printed

scholarly journals Biosensor Based Immunoassay: A New Approach for Serotyping of Toxoplasma gondii

Nanomaterials ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 2065
Author(s):  
Susana Sousa ◽  
António Castro ◽  
José Manuel Correia da Costa ◽  
Eulália Pereira
Keyword(s):  
Gold Nanoparticles ◽  
Toxoplasma Gondii ◽  
Point Of Care ◽  
Colorimetric Method ◽  
Type Ii ◽  
Serum Samples ◽  
Experimental Conditions ◽  
New Approach ◽  
New Methodologies ◽  
Definition Of

Toxoplasmosis is the most reported parasitic zoonosis in Europe, with implications in human health and in the veterinary field. There is an increasing need to develop serotyping of Toxoplasma gondii (T. gondii) in view of greater sensitivity and efficiency, through the definition of new targets and new methodologies. Nanotechnology is a promising approach, with impact in the development of point-of-care devices. The aim of this work was to develop a simple but highly efficient method for Toxoplasma gondii serotyping based on gold nanoparticles. A simple colorimetric method was developed using gold nanoparticles modified with the synthetic polymorphic peptide derived from GRA6 antigen specific for type II T. gondii. The method of preparation of the gold nanoprobes and the experimental conditions for the detection were found to be critical for a sensitive discrimination between positive and negative sera. The optimized method was used to detect antibodies anti-GRA6II both in mice and human serum samples. These results clearly demonstrate that a biosensor-based immunoassay using AuNPs conjugated with polymorphic synthetic peptides can be developed and used as a serotyping device

scholarly journals Discovery of Specific Antigens That Can Predict Microfilarial Intensity inLoa loaInfection

2017 ◽  
Vol 55 (9) ◽  
pp. 2671-2678 ◽  
Author(s):  
Papa M. Drame ◽  
Sasisekhar Bennuru ◽  
Thomas B. Nutman
Keyword(s):  
Point Of Care ◽  
Bioinformatic Analysis ◽  
Potential Utility ◽  
Circulating Biomarkers ◽  
Loa Loa ◽  
Serum Samples ◽  
Blood Samples ◽  
Antigen Capture ◽  
Specific Antigens

ABSTRACTAntigen-based immunoassays are currently needed for point-of-care quantification ofLoa loamicrofilariae (mf). Coupling transcriptomic approaches with bioinformatic analysis, we have identified 11 specific putative proteins (coding mRNAs) with potential utility as biomarkers of patent (mf+)L. loainfection. We successfully developed antigen capture immunoassays to quantify 2 (LOAG_14221 and LOAG_15846) of these proteins in individual plasma/serum samples. Of the 2 quantifiable circulating biomarkers, LOAG_14221 showed the highest degree of specificity, particularly with a monoclonal antibody-based immunoassay. Moreover, the levels of LOAG_14221 inL. loamf+patients were positively correlated to the mf densities in the corresponding blood samples (r= 0.53 andP= 0.008 for polyclonal assay;r= 0.54 andP= 0.004 for monoclonal assay). Thus, LOAG_14221 is a very promising biomarker that will be exploited in a quantitative point-of-care immunoassay for determination ofL. loamf densities.

scholarly journals Diagnosis of SARS-CoV-2 infection

2020 ◽  
Vol 40 (2) ◽  
pp. 50-54
Author(s):  
Tatjana Vilibić-Čavlek ◽  
Ljubo Barbić ◽  
Vladimir Savić ◽  
Maja Bogdanić ◽  
Ljiljana Antolašić ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Neutralization Test ◽  
Point Of Care ◽  
Disease Onset ◽  
Rt Pcr ◽  
Serum Samples ◽  
Detection Rates ◽  
Extent Of Disease ◽  
Negative Detection

The most important use of serology in the COVID-19 diagnostics is for determination of the extent of disease in the population. However, immunoassays could represent an additional diagnostic method, especially in patients with exposure history and clinical symptoms compatible with COVID-19 who failed to be confirmed by RT-PCR. We analyzed the preliminary results of six serology tests for the diagnosis of SARS-CoV-2. Three point-of-care lateral flow chromatographic immunoassays (POC): ACRO, AMP and ENCODE and three enzyme immunoassays (ELISA): DiaPro, Vircell and Euroimmun were used. A total of 15 serum samples from COVID-19 patients and 15 serum samples from asymptomatic persons were tested. Time of sampling for COVID-19 patients was 4 – 10 days (N=4), 11 – 19 days (N=6) and 20 – 34 days (N=5) after disease onset. Initially reactive results were confirmed using a virus neutralization test (VNT). In COVID-19 patients (N=15), IgM/IgA positive detection rates were 9/60.0% (ACRO), 11/73.3% (AMP, ENCODE, Euroimmun), 12/80.0% (DiaPro) and 13/86.6% (Vircell). Overall IgG detection rates were 10//66.6% (AMP, Euroimmun) and 11/73.3% (other tests). According to the sampling time, positive detection rates were as follows: a) days 4 – 10: 1/25.0% and 2/50.0% (IgM/IgA and IgG); b) days 11 –19: 4/66.6%-6/100% (IgM/IgA), 4/66.6% and 5/83.3% (IgG); c) days 20 – 34: 4/80.0% and 5/100% (IgM/IgA), 5/100% (IgG). One asymptomatic participant tested IgM/IgA positive using ACRO, DiaPro and Vircell was confirmed seropositive using a VNT. In a group of asymptomatic persons detected seronegative using a VNT (N=14), IgM/IgA negative detection rates were 12/85.7% (ACRO), 13/92.8% (DiaPro, Vircell) and 14/100% (AMP, ENCODE, Euroimmun). IgG negative detection rates were 13/92.8% (ACRO) and 14/100% (other tests). ELISA tests showed a higher overall IgM/IgA sensitivity compared to POC tests in patients with COVID-19, while the IgG sensitivity was similar in both POC and ELISA.

scholarly journals A Fluorescence System Composed of Nitrogen-doped Graphene Quantum Dots and Gold Nanoparticles Coated With Phenylalanine for Selective and Sensitive Quantification of Piroxicam in Biological Samples

2022 ◽  
Author(s):  
Maryam Moallemi Bahmani ◽  
Ali Mohammad Haji Shabani ◽  
Shayessteh Dadfarnia ◽  
Roya Afsharipour
Keyword(s):  
Quantum Dots ◽  
Gold Nanoparticles ◽  
Limit Of Detection ◽  
Graphene Quantum Dots ◽  
Fluorescence Emission ◽  
Calibration Graph ◽  
Serum Samples ◽  
Nitrogen Doped Graphene ◽  
Doped Graphene

Abstract In this study, a sensitive fluorimetric method is proposed for the determination of piroxicam using nitrogen graphene quantum dots (N-GQDs) and gold nanoparticles coated with phenylalanine. The fluorescence emission of N-GQDs at 440 nm decreases with the increase of gold nanoparticles coated with phenylalanine. However, the addition of piroxicam causes the release of gold nanoparticles from the surface of quantum dots followed by the retrieval of the fluorescence emission of N-GQDs. Under the optimum conditions, the calibration graph was linear in the concentration range of 2.0-35.0 nmol L-1 for piroxicam with a limit of detection of 0.11 nmol L-1. The developed method was successfully applied for the determination of piroxicam in urine and serum samples.

scholarly journals Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination

Diagnostics ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 187
Author(s):  
Aapo Knuutila ◽  
Carita Rautanen ◽  
Jussi Mertsola ◽  
Qiushui He
Keyword(s):  
Point Of Care ◽  
Vaccine Antigen ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Test Platform ◽  
New Type ◽  
Point Of Care Tests ◽  
Spatial Multiplex ◽  
Diagnostic Outcome

Most of the current serological diagnosis of pertussis is based on pertussis toxin (PT) IgG antibodies and does not differentiate between vaccination and infection-induced antibodies. PT is included in all of acellular pertussis vaccines available in the world. Multiplex testing of non-vaccine antigen-related antibodies has the potential to improve the diagnostic outcome of these assays. In this study, we developed a quantitatively spatial multiplex lateral flow immunoassay (LFIA) for the detection of IgG antibodies directed against PT, pertactin (PRN), and filamentous hemagglutinin (FHA). The assay was evaluated with serum samples with varying anti-PT, anti-PRN, and anti-FHA IgG levels and the result was compared to those obtained with standardized ELISA. The developed assay showed good specificity with PT and PRN antibodies and semiquantification throughout the antigen combinations. This exploratory study indicates that the multiplex LFIA is specific and sensitive, and a similar test platform with alternative antigens could be suitable for new type of pertussis serology.

TO DETERMINE THE ROLE OF CA125 IN THE DIAGNOSIS OF ACUTE APPENDICITIS

2020 ◽  
Vol 4 (7) ◽  
Author(s):  
Vinod Kumar ◽  
Bhupen Songra ◽  
Richa Jain ◽  
Deeksha Mehta
Keyword(s):  
Acute Appendicitis ◽  
Clinical Diagnosis ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Ca 125 ◽  
Care Hospital ◽  
Serum Samples ◽  
Roc Curve Analysis ◽  
Surgery Department

Background: the present study was under taken to determine the role of CA-125 in the diagnosis of acute appendicitis (AA), to prevent its complications and also in preventing negative appendicectomies in tertiary care hospital. Methods: The study was conducted at a tertiary care and research center between 01/03/2018 to 30/06/2019. Patients admitted to the surgery department with diagnosis of AA were considered for the study. After informed consent, a, standardized history was obtained as a case Performa. Serum samples from all the cases with clinical diagnosis of AA were obtained and stored. Only the cases with histopathologically approved AA were included in the study. Cases operated for clinical diagnosis of AA, but not histopathologically proven AA was not included in the study. CA125 levels in cases with definitive diagnosis of AA were measured. Results: In present study, ROC curve analysis revealed the sensitivity of 87.27 % and specificity of 90.91 % when the CA 125 cut-off value of > 16.8 was taken to diagnose acute appendicitis. AUC was 0.911 with a standard error of 0.0292. Conclusion: In this study we have observed that CA125 showed a positive correlation with acute appendicitis, that was statistically not significant (P>0.05). We didn’t evaluate the correlation with the disease severity. We consider that CA125 can be used as a marker in acute appendicitis cases although further research is still needed. Keywords: CA125, Acute Appendicitis, Surgery.

Ferromagnetic Resonance Biosensor for Homogeneous and Volumetric Detection of DNA

2017 ◽  
Author(s):  
Bo Tian ◽  
Peter Svedlindh ◽  
Mattias Strömberg ◽  
Erik Wetterskog
Keyword(s):  
Magnetic Nanoparticles ◽  
Ferromagnetic Resonance ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Rolling Circle Amplification ◽  
Resonance Field ◽  
Isothermal Amplification ◽  
Detection Sensitivity ◽  
Serum Samples ◽  
Rolling Circle

In this work, we demonstrate for the first time, a ferromagnetic resonance (FMR) based homogeneous and volumetric biosensor for magnetic label detection. Two different isothermal amplification methods, <i>i.e.</i>, rolling circle amplification (RCA) and loop-mediated isothermal amplification (LAMP) are adopted and combined with a standard electron paramagnetic resonance (EPR) spectrometer for FMR biosensing. For RCA-based FMR biosensor, binding of RCA products of a synthetic Vibrio cholerae target DNA sequence gives rise to the formation of aggregates of magnetic nanoparticles. Immobilization of nanoparticles within the aggregates leads to a decrease of the net anisotropy of the system and a concomitant increase of the resonance field. A limit of detection of 1 pM is obtained with an average coefficient of variation of 0.16%, which is superior to the performance of other reported RCA-based magnetic biosensors. For LAMP-based sensing, a synthetic Zika virus target oligonucleotide is amplified and detected in 20% serum samples. Immobilization of magnetic nanoparticles is induced by their co-precipitation with Mg<sub>2</sub>P<sub>2</sub>O<sub>7</sub> (a by-product of LAMP) and provides a detection sensitivity of 100 aM. The fast measurement, high sensitivity and miniaturization potential of the proposed FMR biosensing technology makes it a promising candidate for designing future point-of-care devices.<br>

Sign in / Sign up

Export Citation Format

Share Document